11 Biopharma Trends to Watch in 2024 https://buff.ly/3VWtJMr
This Week in Digital Health’s Post
More Relevant Posts
-
Introducing a new edition of our #SummerReads series at #Ardena. In our recent #whitepaper, "Deciphering the Complex Characteristics of Nanoparticles by Asymmetric Flow Field-Flow Fractionation," we explore the fascinating world of engineered #nanoparticles in drug delivery. Nanoparticles have emerged as customizable drug delivery platforms, enabling precise and efficient delivery of drugs to specific targets in the body. Learn about the various nanoparticulate systems, their unique physicochemical properties, and how we optimize them for specific applications. The whitepaper explores the challenges faced in drug development, regulatory pathways, and the potential of nanoparticle-based therapies. Our experts employ asymmetric flow field-flow fractionation (AF4) coupled with multi-angle light scattering (MALS) and dynamic light scattering (DLS) to conduct comprehensive, in-depth characterization. This method allows us to study particle size distribution, molar mass distribution, aggregation, and morphology of nanoparticles. Read the full whitepaper here: https://lnkd.in/dgYp9B9U And stay tuned for our next Summer Reads series installment! #Nanomedicines #Nanoparticles #DrugDelivery #AF4 #DrugDevelopment #TargetedTherapeutics
Ardena Summer Reads - Deciphering the Complex Characteristics of Nanoparticles by Asymmetric Flow Field-Flow Fractionation
ardena.com
To view or add a comment, sign in
-
Our colleagues will be presenting at the upcoming CHI’s Drug Discovery Chemistry Conference between the 1st-4th April in San Diego, California. If you are attending the conference, check out the oral presentations below. Astex Oral Presentations: 1. Marcel Verdonk - Scale-Up Your Experts: Harnessing AI for Augmented Fragment-Based Drug Discovery 2. Tom Davies - Fragment-based discovery of allosteric SHP2 inhibitors 3. Alex Berndt - Structure based approaches to uncover distinct binding modes of covalent and non-covalent CDK7 clinical candidates #DrugDiscovery #Fragments #AI
Drug Discovery Chemistry | April 1-4, 2024 | San Diego, CA
drugdiscoverychemistry.com
To view or add a comment, sign in
-
Watch this for a great overview of the current applications for #MMS technology.
Review our latest talk, delivered by Patrick King PhD last week at Formulation and Delivery UK! Patrick's overview of MMS fundamentals and the exciting possibilities for RNA analysis and precise detection of characteristic structural shifts drove highly engaged traffic to our booth for dynamic and fruitful discussions. Dr. King covers our Aurora system’s in situ capabilities, tackling both simple and complex buffers effortlessly, and highlights how Aurora’s Quantum Cascade Laser and microfluidic flow cell help achieve sensitivity levels up to 30 times higher than traditional spectroscopic methods. From QC assessments to ligand binding studies, Aurora is a versatile tool for structural elucidation across the biopharmaceutical pipeline. Watch on Demand!: https://lnkd.in/e-pu2JWK #FormulationSeries24 #DrugDelivery #DrugDevelopement #RNAstructure #RNAtherapeutics #biopharma #innovation
To view or add a comment, sign in
-
During PK studies, scientists and R&D directors often struggle with high sample volumes and manual pipetting in their #immunoassay workflow. How can microfluidic technology enhance lab processes and boost productivity? Click below to learn how! 🚀 #Biotech #Bioanalysis #pharmacokinetics https://lnkd.in/gRcnzXwh
How to Address ELISA Challenges in Preclinical PK Studies with Advanced Microfluidic Technology
gyrosproteintechnologies.com
To view or add a comment, sign in
-
Watch my presentation at Formulation and Delivery, London, last week here to learn more about Aurora and MMS! Including examples of applications for proteins, peptides and mRNA!
Review our latest talk, delivered by Patrick King PhD last week at Formulation and Delivery UK! Patrick's overview of MMS fundamentals and the exciting possibilities for RNA analysis and precise detection of characteristic structural shifts drove highly engaged traffic to our booth for dynamic and fruitful discussions. Dr. King covers our Aurora system’s in situ capabilities, tackling both simple and complex buffers effortlessly, and highlights how Aurora’s Quantum Cascade Laser and microfluidic flow cell help achieve sensitivity levels up to 30 times higher than traditional spectroscopic methods. From QC assessments to ligand binding studies, Aurora is a versatile tool for structural elucidation across the biopharmaceutical pipeline. Watch on Demand!: https://lnkd.in/e-pu2JWK #FormulationSeries24 #DrugDelivery #DrugDevelopement #RNAstructure #RNAtherapeutics #biopharma #innovation
To view or add a comment, sign in
-
Nikki Carter, our Director of Commercial Organoid Innovation, leverages decades of experience in large pharmaceutical companies to help researchers optimize organoid-based drug discovery and high-throughput screening programs. Check out her latest published perspectives on these topics and more: https://ow.ly/Xxm350SzKrR. ✏️ A Three-Pillar Approach to Driving Organoid Adoption in Drug Discovery: https://ow.ly/y6sq50SzKrQ ✏️ Patient-Derived Organoids in Disease Modeling: https://ow.ly/RAgJ50SzKrS #3dbiology #3dcellculture #organoids #drugdiscovery #drugscreening #drugdevelopment #diseasemodeling #labautomation #ai #machinelearning #deeplearning #highcontentimaging #highcontentscreening #scienceandtechnology #pharma #geneeditting #cellculture #pdo #imageanalysis
Nikki Carter's Expert Perspectives on 3D Biology
moleculardevices.com
To view or add a comment, sign in
-
#Biorepositories that collect, process, and store #biospecimens such as tissues, blood, DNA, and cells at subzero temperatures are crucial for advancing drug research, development, and manufacturing. These facilities ensure the integrity of essential biological materials, facilitating breakthroughs in understanding disease mechanisms and accelerating the development of #innovativetherapies. When establishing a #biorepository, #biotechnology and #pharmaceutical companies have two choices: They can either construct one from scratch, or they can purchase space in an existing facility. Our new article breaks down this topic, exploring the advantages of building vs. buying a biorepository. It also discusses how #CDMO partners like Thermo Fisher Scientific can provide storage support. You can read it here: http://spr.ly/6049jU6WZ
Pros of building vs buying a biorepository
patheon.com
To view or add a comment, sign in
-
Interested in the future of biotech and biopharma in 2024? As we gear up for the new year, it’s essential to understand the evolving landscape in these industries. Here’s a sneak peek into what awaits us: https://lnkd.in/g8Xa7mbp
6 Predictions Biotech and Biopharma Should Know in 2024 ⋆ Vial
https://vial.com
To view or add a comment, sign in
-
What can you do with our unique MAGNA™ technology? One application is to study RNA-ligand binding. Here’s how it works… 🧲 MAGNA is based on magnetic force spectroscopy (MFS). This technique directly measures the forces involved in biomolecular interactions - between DNA, RNA, proteins and small molecules - in real-time. ⚙️ MAGNA has harnessed the power of MFS, making it accessible and scalable for the first time for the biopharma research community. 📈 Force ramp experiments stretch and release target RNA molecules through multiple cycles of increasing and decreasing forces, measuring the force required to linearise three-dimensional RNA structures in the presence or absence of ligands such as small molecules or proteins. 🔗 This reveals the binding affinities of ligands and whether they stabilize or destabilize their RNA targets. This can be done across a range of concentrations to observe the dose-dependency of a drug or binding protein. Curious to learn more, and hear how else MAGNA can be used? In our recent webinar, our CEO Gordon Hamilton covers real-life case studies showcasing different applications of MAGNA. Watch our webinar now: https://lnkd.in/de4vejj4 and connect with us here on LinkedIn to discuss how MAGNA can accelerate your RNA-targeted drug discovery. #RNATherapeutics #DrugDiscovery #Biotech #ScientificResearch
WEBINAR: Transforming RNA-targeted drug discovery with MAGNA™
https://depixus.com
To view or add a comment, sign in
-
Senior Research Fellow @ NTU | Advisor @ Singzyme | Protein Biochemistry | Antibody Drug Conjugates | Biotech | Operation manager |
🎙️ Excited to be Speaking at the Inaugural ADC Linker & Conjugation Summit! 🎉 I am thrilled to announce that I will be speaking at the prestigious ADC Linker & Conjugation Summit, a groundbreaking event dedicated to optimizing ADCs chemistry and advancing the world of targeted therapies! Join me and over 80 esteemed colleagues for this industry-specific meeting aimed at bringing ADCs with a wider therapeutic index to patients in need. As the CEO of Singzyme, a pioneering startup with a core technology centered around Peptide Asparaginyl Ligases (PALs) for conjugating active drugs and payloads to proteins, I am honored to share our ground breaking platform for antibodies and nanobodies engineering and conjugation. Our integrated, high-speed, precision bio-manufacturing solution is designed to address the challenges faced by Antibody Drug Conjugates (ADCs) developers, transforming the way bioconjugates are manufactured. The potential of ADCs to precisely deliver therapeutic payloads to target cells holds immense promise for improving patient outcomes. However, the manufacturing process has been a bottleneck, hindering the full realization of this potential. Singzyme's platform offers a one-stop solution to streamline ADC production, enabling researchers and developers to focus on delivering more effective and safer treatments to patients. At the summit, I will be sharing insights into the latest advancements in ADC conjugation and linker technologies, shedding light on how Singzyme's innovation can play a pivotal role in the future of targeted therapies. Additionally, I look forward to learning from other experts in the field and exploring collaborative opportunities that will shape the future of ADC development and patient care. I invite all of you who are passionate about advancing the field of targeted therapies and exploring cutting-edge bioconjugation techniques to join me at the ADC Linker & Conjugation Summit. Let's come together to drive innovation, accelerate research, and ultimately bring transformative treatments to patients worldwide. See you at the summit! 🌐 #ADCConjugation #TargetedTherapies #Singzyme #Bioconjugates #Innovation #PatientCare #ADCsummit2023 https://ter.li/zh27vh
Home - ADC Linker & Conjugation Summit
adc-linker-conjugation.com
To view or add a comment, sign in
24,893 followers